{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T04:15:07Z","timestamp":1784175307118,"version":"3.55.0"},"reference-count":33,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"23","license":[{"start":{"date-parts":[[2020,6,5]],"date-time":"2020-06-05T00:00:00Z","timestamp":1591315200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:sec>\n            <jats:title>Abstract<\/jats:title>\n            <jats:p>Tirofiban is widely used in patients with acute ST elevation myocardial infarction (STEMI) underwent percutaneous coronary intervention (PCI). This drug can efficiently improve myocardial perfusion and cardiac function, but its dose still remains controversial. We here investigated the effects of different dose of tirofiban on myocardial reperfusion and heart function in patients with STEMI. A total of 312 STEMI patients who underwent PCI in our hospital from March 2017 to March 2018 were enrolled and randomly divided into control group (75 cases, 0\u200a\u03bcg\/kg), low-dose group (79 cases, 5\u200a\u03bcg\/kg), medium-dose group (81 cases, 10\u200a\u03bcg\/kg) and high-dose group (77 cases, 20\u200a\u03bcg\/kg). The infarction-targeted artery flow grade evaluated by thrombolysis in myocardial infarction (TIMI), corrected TIMI frame count (CTFC) and sum-ST-segment resolution were recorded. At Day 7 and Day 30 after PCI, the left ventricular ejection fraction (LVEF), left ventricular end diastolic diameter, left ventricular end systolic diameter, major adverse cardiovascular events and the hemorrhage and thrombocytopenia were also evaluated. After PCI, the rate of TIMI grade 3, CTFC and incidence of sum-ST-segment resolution &gt; 50% of high-dose group were significantly higher than those of control group, low-dose group and medium-dose group (<jats:italic toggle=\"yes\">P<\/jats:italic>\u200a&lt;\u200a.05), and the CTFC of medium -dose group were significantly higher than that of control group, low-dose group (<jats:italic toggle=\"yes\">P<\/jats:italic>\u200a&lt;\u200a.05). Moreover, the LVEF, left ventricular end diastolic diameter and left ventricular end systolic diameter of high-dose group were significantly improved than those of other groups, and the LVEF of medium-dose group was significantly superior to that of low-dose group (<jats:italic toggle=\"yes\">P<\/jats:italic>\u200a&lt;\u200a.05). However, the incidence of major adverse cardiac events in high-dose group was significantly decreased, while the hemorrhage and incidence of thrombocytopenia of high-dose group were significantly higher than those of other 3 groups (<jats:italic toggle=\"yes\">P<\/jats:italic>\u200a&lt;\u200a.05). The tirofiban can effectively alleviate the myocardial ischemia-reperfusion injury and promote the recovery of cardiac function in STEMI patients underwent PCI. Although the high-dose can enhance the clinical effects, it also increased the hemorrhagic risk. Therefore, the rational dosage application of tirofiban become much indispensable in view of patient's conditions and hemorrhagic risk, and a medium dose of 10\u200a\u03bcg\/kg may be appropriate for patients without high hemorrhagic risk.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000020402","type":"journal-article","created":{"date-parts":[[2020,6,3]],"date-time":"2020-06-03T20:01:58Z","timestamp":1591214518000},"page":"e20402","source":"Crossref","is-referenced-by-count":15,"title":["Influences of different dose of tirofiban for acute ST elevation myocardial infarction patients underwent percutaneous coronary intervention"],"prefix":"10.1097","volume":"99","author":[{"given":"Haixia","family":"Wang","sequence":"first","affiliation":[{"name":"Department Pharmacy, the Second Clinical Hospital of Shanxi Medical University, Taiyuan, Shanxi"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meiqin","family":"Feng","sequence":"additional","affiliation":[{"name":"AstraZeneca (Wuxi) trading co. LTD, Wuxi, Jiangsu, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,6,5]]},"reference":[{"key":"R1-20230915","doi-asserted-by":"crossref","first-page":"572","DOI":"10.4067\/S0034-98872017000500003","article-title":"Prediction of hospital mortality of ST elevation myocardial infarction using TIMI score","volume":"145","author":"Ugalde","year":"2017","journal-title":"Rev Med Chil"},{"key":"R2-20230915","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1002\/clc.22655","article-title":"ST-elevation acute myocardial infarction in pregnancy: 2016 update","volume":"40","author":"Ismail","year":"2017","journal-title":"Clin Cardiol"},{"key":"R3-20230915","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ijcard.2018.02.010","article-title":"Coronary microembolization and microvascular dysfunction","volume":"258","author":"Heusch","year":"2018","journal-title":"Int J Cardiol"},{"key":"R4-20230915","doi-asserted-by":"crossref","first-page":"369","DOI":"10.2147\/TCRM.S158768","article-title":"Renoprotective effect of remote ischemic postconditioning in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention","volume":"22","author":"Cao","year":"2018","journal-title":"Ther Clin Risk Manag"},{"key":"R5-20230915","doi-asserted-by":"crossref","first-page":"e10850","DOI":"10.1097\/MD.0000000000010850","article-title":"Effect of intra-coronary administration of tirofiban through aspiration catheter on patients over 60 years with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention","volume":"97","author":"Sigan","year":"2018","journal-title":"Medicine"},{"key":"R6-20230915","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.ihj.2017.02.002","article-title":"Association of testosterone, inflammation with the severity of first acute ST-elevation myocardial infarction","volume":"69","author":"Wickramatilake","year":"2017","journal-title":"Indian Heart J"},{"key":"R7-20230915","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.recesp.2016.06.024","article-title":"Intravascular ultrasound predictors of major adverse cardiovascular events after implantation of everolimus-eluting stents for long coronary lesions","volume":"70","author":"Lee","year":"2017","journal-title":"Rev Esp Cardiol"},{"key":"R8-20230915","doi-asserted-by":"crossref","first-page":"899","DOI":"10.5152\/akd.2014.5656","article-title":"The effects of tirofiban infusion on clinical and angiographic outcomes of patients with STEMI undergoing primary PCI","volume":"15","author":"Kaymaz","year":"2015","journal-title":"Anatol J Cardiol"},{"key":"R9-20230915","doi-asserted-by":"crossref","first-page":"e14673","DOI":"10.1097\/MD.0000000000014673","article-title":"The efficacy and safety of tirofiban for patients with acute ischemic stroke: a protocol for systematic review and a meta-analysis","volume":"98","author":"Niu","year":"2019","journal-title":"Medicine"},{"key":"R10-20230915","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.amjcard.2018.09.029","article-title":"Comparison of in-hospital bleeding and cardiovascular events with high-dose bolus tirofiban and shortened infusion to short-duration eptifibatide as adjunctive therapy for percutaneous coronary intervention","volume":"123","author":"Anderson","year":"2019","journal-title":"Am J Cardiol"},{"key":"R11-20230915","doi-asserted-by":"crossref","first-page":"145","DOI":"10.2174\/1567202615666180605104931","article-title":"Safety and efficiency of low dose intra-arterial tirofiban in mechanical thrombectomy during acute ischemic stroke","volume":"15","author":"Yu","year":"2018","journal-title":"Curr Neurovasc Res"},{"key":"R12-20230915","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.jacc.2015.11.010","article-title":"Transatlantic comparison of ST-segment elevation myocardial infarction guidelines: insights from the United States and Europe","volume":"67","author":"Bainey","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"R13-20230915","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1007\/s12928-018-0516-y","article-title":"CVIT expert consensus document on primary percutaneous coronary intervention (PCI) for acute myocardial infarction (AMI) in 2018","volume":"33","author":"Yukio","year":"2018","journal-title":"Cardiovasc Interv Ther"},{"key":"R14-20230915","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1109\/TUFFC.2016.2518306","article-title":"Realtime automatic assessment of cardiac function in echocardiography","volume":"63","author":"Storve","year":"2016","journal-title":"IEEE Trans Ultrason Ferroelectr Freq Control"},{"key":"R15-20230915","doi-asserted-by":"crossref","first-page":"581","DOI":"10.2217\/cer-2016-0017","article-title":"Risk assessment in patients with an acute ST-elevation myocardial infarction","volume":"5","author":"Ahmed","year":"2016","journal-title":"J Comp Eff Res"},{"key":"R16-20230915","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/j.carrev.2018.11.021","article-title":"Role of intracoronary fibrinolytic therapy in contemporary PCI practice","volume":"20","author":"Agarwal","year":"2019","journal-title":"Cardiovasc Revasc Med"},{"key":"R17-20230915","doi-asserted-by":"crossref","first-page":"3549","DOI":"10.12659\/MSM.908980","article-title":"The value of combining plasma D-dimer and endothelin-1levels to predict no-reflow after percutaneous coronary intervention of ST-segment elevation in acute myocardial infarction patients with a type 2 diabetes mellitus history","volume":"24","author":"Gao","year":"2018","journal-title":"Med Sci Monit"},{"key":"R18-20230915","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s12471-018-1121-5","article-title":"Anticoagulation and antiplatelet therapy in acute coronary syndromes: choosing between the Scylla of bleeding and the Charybdis of ischaemic events","volume":"26","author":"De Winter","year":"2018","journal-title":"Neth Heart J"},{"key":"R19-20230915","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1016\/j.cjca.2019.05.003","article-title":"Routine glycoprotein IIb\/IIIa inhibitor therapy in ST-segment elevation myocardial infarction: a meta-analysis","volume":"35","author":"Karathanos","year":"2019","journal-title":"Can J Cardiol"},{"key":"R20-20230915","first-page":"11360","article-title":"Efficacy and safety of different doses of tirofiban combined with ticagrelor on diabetic patients withAMI receiving in emergency percutaneous coronary intervention (PCI)","volume":"8","author":"Liu","year":"2015","journal-title":"Int J Clin Exp Med"},{"key":"R21-20230915","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s10555-017-9683-z","article-title":"Antiplatelet agents for cancer treatment: a real perspective or just an echo from the past?","volume":"36","author":"Wojtukiewicz","year":"2017","journal-title":"Cancer Metastasis Rev"},{"key":"R22-20230915","first-page":"3276","article-title":"Evaluation on the safety and efficacy of high-dose tirofiban in the primary percutaneous coronary intervention on patients with acute ST-elevation myocardial infarction","volume":"18","author":"Wang","year":"2015","journal-title":"Chin Gen Prac"},{"key":"R23-20230915","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.3892\/etm.2015.2401","article-title":"Effects of different routes of tirofiban injection on the left ventricular function and prognosis of patients with myocardial infarction treated with percutaneous coronary intervention","volume":"9","author":"Zhao","year":"2015","journal-title":"Exp Ther Med"},{"key":"R24-20230915","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1007\/s12471-018-1112-6","article-title":"Optimal pharmacological therapy in ST-elevation myocardial infarction-a review: a review of antithrombotic therapies in STEMI","volume":"26","author":"Hermanides","year":"2018","journal-title":"Neth Heart J"},{"key":"R25-20230915","first-page":"614","article-title":"Combined thrombectomy and intracoronary administration of glycoprotein IIb\/IIIa inhibitors improves myocardial reperfusion in patients undergoing primary percutaneous coronary intervention: a meta-analysis","volume":"14","author":"Niu","year":"2017","journal-title":"J Geriatr Cardiol"},{"key":"R26-20230915","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.carrev.2017.06.009","article-title":"Intracoronary high-dose bolus tirofiban administration during complex coronary interventions: a United States-based case series","volume":"19","author":"Wilmer","year":"2018","journal-title":"Cardiovasc Revasc Med"},{"key":"R27-20230915","first-page":"126","article-title":"High-dose bolus tirofiban versus low-dose bolus in patients with acute coronary syndrome undergoing percutaneous coronary intervention","volume":"45","author":"Ulus","year":"2017","journal-title":"Turk Kardiyol Dern Ars"},{"key":"R28-20230915","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/s11883-019-0782-x","article-title":"Optimal antithrombotic therapy for patients with STEMI undergoing PCI at high risk of bleeding","volume":"21","author":"Tu","year":"2019","journal-title":"Curr Atheroscler Rep"},{"key":"R29-20230915","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1136\/heartjnl-2017-311181","article-title":"Long-term mortality and prehospital tirofiban treatment in patients with ST elevation myocardial infarction","volume":"103","author":"Fabris","year":"2017","journal-title":"Heart"},{"key":"R30-20230915","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1177\/0003319718808911","article-title":"Effects of bailout Tirofiban on in-hospital outcomes and long-term mortality in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous intervention","volume":"70","author":"Velibey","year":"2019","journal-title":"Angiology"},{"key":"R31-20230915","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s00228-019-02817-8","article-title":"Tirofiban for acute ischemic stroke: systematic review and meta-analysis","volume":"76","author":"Gong","year":"2020","journal-title":"Eur J Clin Pharmacol"},{"key":"R32-20230915","first-page":"3383","article-title":"Effects of tirofiban on stent thrombosis, Hs-CRP, IL-6 and sICAM-1 after PCI of acute myocardial infarction","volume":"16","author":"Zhang","year":"2018","journal-title":"Exp Ther Med"},{"key":"R33-20230915","doi-asserted-by":"crossref","first-page":"e399","DOI":"10.1055\/s-0038-1675576","article-title":"Comparison of ACUITY, CRUSADE, and GRACE risk scales for predicting clinical outcomes in patients treated with dual-antiplatelet therapy","volume":"2","author":"Choi","year":"2018","journal-title":"TH Open"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000020402","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,16]],"date-time":"2023-09-16T00:05:37Z","timestamp":1694822737000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000020402"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,5]]},"references-count":33,"journal-issue":{"issue":"23","published-online":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000020402","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,5]]}}}